Innovative Medicine
-
New Data Confirms Circulating Tumor Cells Are Useful Predictors of Progression-free and Overall Survival
First Study to Demonstrate Value of Circulating Tumor Cell Enumeration in Chinese Metastatic Breast Cancer Patients Published in Annals of Oncology -
SIMPONI® ARIA™ (golimumab) for infusion Receives FDA Approval for TREATMENT OF MODERATELY TO SEVERELY ACTIVE Rheumatoid arthritis
First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis -
-
New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of Two B-Cell Malignancies
If approved, ibrutinib will address a high unmet need in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma -
Mentor Announces Collaboration Agreement With Valeant Pharmaceuticals
New physician loyalty program offers broad portfolio of aesthetic products -
-
CHMP Gives A Positive Opinion For The Use Of VELCADE® As Retreatment And For Frontline Induction Therapy Before Stem Cell Transplantation
Label updates could lead to significantly improved outcomes for patients with multiple myeloma -
Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes
Phase 3 Results for INVOKANA™ Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure -
Ibrutinib Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Data Published in The New England Journal of Medicine
A second study in relapsed/refractory mantle cell lymphoma (MCL) also published in the online edition